Loading…
Loading…
EQUITY / NASDAQ · XNCM
Ensysce Biosciences, Inc. Common Stock
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.4158 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 0.4158 USD · Volume 348,444
680 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Revenue | 1,164,315 USD | — | — |
| Operating profit | -2,576,389 USD | — | — |
| Net income | -2,570,875 USD | — | — |
| Cash and cash equivalents | 676,704 USD | — | — |
| Total liabilities | 4,068,106 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 203/31/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 101/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 676,704 USD | — | — | 745,482 USD | 4,310,354 USD | 4,310,354 USD | 1,673,218 USD | — |
| Net incomeIncome statement | -2,570,875 USD | -6,127,290 USD | — | -3,556,415 USD | — | -10,176,187 USD | -3,729,128 USD | -7,408,218 USD |
| Operating profitIncome statement | -2,576,389 USD | -6,138,619 USD | — | -3,562,230 USD | — | -10,240,946 USD | -3,741,095 USD | -7,459,121 USD |
| RevenueIncome statement | 1,164,315 USD | 2,125,313 USD | — | 960,999 USD | — | 5,066,650 USD | 493,104 USD | 3,184,314 USD |
| Total assetsBalance sheet | 2,957,273 USD | — | — | 2,167,803 USD | 7,452,479 USD | 7,452,479 USD | 3,179,464 USD | — |
| Total equityBalance sheet | -781,697 USD | — | -669,012 USD | -340,042 USD | 3,213,720 USD | 3,213,720 USD | 1,203,363 USD | — |
| Total liabilitiesBalance sheet | 4,068,106 USD | — | — | 2,836,815 USD | 4,567,729 USD | 4,567,729 USD | 2,304,750 USD | — |
| Financing cash flowCash flow statement | — | 1,829,733 USD | — | -63,947 USD | — | 8,738,212 USD | — | 4,575,243 USD |
| Operating cash flowCash flow statement | — | -5,463,383 USD | — | -3,500,925 USD | — | -7,806,292 USD | — | -6,280,459 USD |
| Capital expendituresCash flow statement | — | — | — | — | — | 123,643 USD | — | 123,643 USD |
| Investing cash flowCash flow statement | — | — | — | — | — | -123,643 USD | — | -123,643 USD |
| Report source | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 03/30/2026 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 11/14/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.